دورية أكاديمية

P895: DARATUMUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE (DPD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND 17P DELETION: UPDATED ANALYSIS OF THE DEDALO PHASE II TRIAL.

التفاصيل البيبلوغرافية
العنوان: P895: DARATUMUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE (DPD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND 17P DELETION: UPDATED ANALYSIS OF THE DEDALO PHASE II TRIAL.
المؤلفون: Montefusco, Vittorio, Maria Cafro, Anna, Margiotta‐Casaluci, Gloria, Patriarca, Francesca, Mina, Roberto, D’agostino5, Mattia, Palma, Anna Benedetta Dalla, Rizzi, Rita, Genua, Angelo, Fazio, Francesca, Paris, Laura, Belotti, Angelo, Rizzello, Ilaria, Conticello, Concetta, Carlo‐Stella, Carmelo, Boccadoro, Mario
المصدر: HemaSphere; 2023 Supplement 3, Vol. 7, p1-2, 2p
قاعدة البيانات: Complementary Index
الوصف
تدمد:25729241
DOI:10.1097/01.HS9.0000970484.72978.5d